お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
967283

デュシェンヌ型筋ジストロフィー (DMD) - 世界の臨床試験レビュー

Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020

出版日: | 発行: GlobalData | ページ情報: 英文 211 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
デュシェンヌ型筋ジストロフィー (DMD) - 世界の臨床試験レビュー
出版日: 2020年10月06日
発行: GlobalData
ページ情報: 英文 211 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のデュシェンヌ型筋ジストロフィー (DMD) の臨床試験について調査分析し、臨床試験シナリオの概要、治験数、平均登録数のほか、世界の治験情勢、主要データ、主要企業などについて、体系的な情報を提供しています。

目次

  • ガイダンス
  • 調査範囲
  • 臨床試験:地域別
  • 臨床試験:G7諸国別 - 遺伝性疾患の臨床試験に対するデュシェンヌ型筋ジストロフィー (DMD) の割合
  • 臨床試験:G7諸国のフェーズ別
  • G7諸国の臨床試験:治験ステータス別
  • 臨床試験:E7諸国別 - 遺伝性疾患の臨床試験に対するデュシェンヌ型筋ジストロフィー (DMD) の割合
  • 臨床試験:E7諸国のフェーズ別
  • E7諸国の臨床試験:治験ステータス別
  • 臨床試験:フェーズ別
  • 進行中の治験:フェーズ別
  • 臨床試験:治験ステータス別
  • 臨床試験:評価項目ステータス別
  • 一定期間募集された被験者数
  • 臨床試験:スポンサータイプ別
  • 有力なスポンサー
  • 有力な医薬品
  • 臨床試験プロファイルのスナップショット

付録

図表

List of Tables

  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Gl

List of Figures

  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology
目次
Product Code: GDHC6438CTIDB

GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Source
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.